Michael S. Rafii, MD, PhD

Title(s)Professor of Clinical Neurology
SchoolKeck School of Medicine of Usc
AddressATR 9860 Mesa Rim Road
Health Sciences Campus
San Diego CA 92121
Phone+1 858 964 0638
vCardDownload vCard
    Other Positions
    Title(s)Associate Director of ACTC (Alzheimer's Clinical Trial Consortium) and Director of Medical Safety

    Collapse Biography 
    Collapse Awards and Honors
    Brown University School of Medicine2002Aronson Prize for Excellence in Neuroscience
    The Johns Hopkins University/Sinai Hospital2003Intern of the Year
    The Johns Hopkins Hospital2006Preziosi Outstanding Neurology Resident Award
    The Johns Hopkins Hospital2006Alpha Omega Alpha
    LuMind Down Syndrome Research Foundation2016David Cox Award
    Alzheimer’s Association 2022Research Champion Award

    Collapse Overview 
    Collapse Overview
    Michael S. Rafii is Medical Director of the Alzheimer’s Therapeutic Research Institute (ATRI) and Professor of Clinical Neurology at the Keck School of Medicine. He obtained his MD and PhD degrees from Brown University and conducted neurogenetics research at Harvard Medical School. He completed his residency in Neurology at the Johns Hopkins Hospital and fellowship in Neurodegenerative diseases at the University of California, San Diego.

    Dr. Rafii is a physician-scientist whose research focuses on developing new treatments for Alzheimer’s disease (AD) including a genetic form of AD that occurs in people with Down syndrome (DS). He is Principal Investigator of the NIH-funded Alzheimer’s Clinical Trials Consortium - Down Syndrome (ACTC-DS), where he leads several clinical trials across an international network of academic research sites.

    Dr. Rafii also serves as Director of the Medical Safety Unit of the Alzheimer’s Clinical Trials Consortium (ACTC) where he and his team of medical monitors and clinical monitors provide oversight to the safety and conduct of ACTC’s entire portfolio of clinical trials. He is also Co-Director of the Clinical core of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) and Co-Principal Investigator of the national Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET). Dr. Rafii serves as a scientific reviewer for the NIH and the Alzheimer's Association. He is author of two of the most widely used review books in neurology: ‘First Aid for the Neurology Boards’ and ‘First Aid for the Neurology Clerkship.’ His work has been featured in the New York Times, Chicago Tribune, Washington Post, Wall Street Journal and National Public Radio (NPR).

    Previously, Dr. Rafii served as Medical Director of the Alzheimer’s Disease Cooperative Study, Director of the Memory Disorders Clinic, Founding Director of the Adult Down Syndrome Clinic, Director of the Comprehensive Alzheimer’s Program, Director of the Adult Neurology Residency Training program and Associate Professor of Neurology at the University of California, San Diego.

    Collapse Research 
    Collapse Research Activities and Funding
    Precision Medicine for Inflammatory Treatment for Alzheimer's Disease in Down Syndrome
    NIH R01AG073979Sep 30, 2021 - Aug 31, 2024
    Role: Co-Principal Investigator
    Clinical trials to prevent Alzheimer's Disease in Down Syndrome
    NIH R61AG066543Sep 15, 2019 - Aug 31, 2021
    Role: Principal Investigator
    NIH R01AG047922Aug 15, 2014 - Jun 30, 2019
    Role: Principal Investigator
    Alzheimer's Disease Cooperative Study
    NIH U19AG010483Jul 1, 1997 - Feb 28, 2021
    Role: Co-Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Assessing amyloid PET positivity and cognitive function in Down syndrome to guide clinical trials targeting amyloid. Alzheimers Dement. 2024 Jun 28. Krasny S, Yan C, Hartley SL, Handen BL, Wisch JK, Boehrwinkle AH, Ances BM, Rafii MS, ABC-DS consortium. PMID: 38940611.
      View in: PubMed   Mentions:    Fields:    
    2. Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer's disease: a cross-sectional study. Lancet Neurol. 2024 May; 23(5):500-510. Wisch JK, McKay NS, Boerwinkle AH, Kennedy J, Flores S, Handen BL, Christian BT, Head E, Mapstone M, Rafii MS, O'Bryant SE, Price JC, Laymon CM, Krinsky-McHale SJ, Lai F, Rosas HD, Hartley SL, Zaman S, Lott IT, Tudorascu D, Zammit M, Brickman AM, Lee JH, Bird TD, Cohen A, Chrem P, Daniels A, Chhatwal JP, Cruchaga C, Ibanez L, Jucker M, Karch CM, Day GS, Lee JH, Levin J, Llibre-Guerra J, Li Y, Lopera F, Roh JH, Ringman JM, Supnet-Bell C, van Dyck CH, Xiong C, Wang G, Morris JC, McDade E, Bateman RJ, Benzinger TLS, Gordon BA, Ances BM, Alzheimer's Biomarker Consortium-Down syndrome, Dominantly Inherited Alzheimer Network. PMID: 38631766; PMCID: PMC11209765.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. From understanding to action: Exploring molecular connections of Down syndrome to Alzheimer's disease for targeted therapeutic approach. Alzheimers Dement (Amst). 2024 Apr-Jun; 16(2):e12580. Sukreet S, Rafii MS, Rissman RA. PMID: 38623383; PMCID: PMC11016820.
      View in: PubMed   Mentions: 1  
    4. Addressing challenges in health care and research for people with Down syndrome. Lancet. 2024 Mar 20. Fortea J, McGlinchey E, Espinosa JM, Rafii MS. PMID: 38521088.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    5. Neuroimaging abnormalities associated with immunotherapy responsiveness in Down syndrome regression disorder. Ann Clin Transl Neurol. 2024 Apr; 11(4):1034-1045. Santoro JD, Khoshnood MM, Jafarpour S, Nguyen L, Boyd NK, Vogel BN, Kammeyer R, Patel L, Manning MA, Rachubinski AL, Filipink RA, Baumer NT, Santoro SL, Franklin C, Tamrazi B, Yeom KW, Worley G, Espinosa JM, Rafii MS. PMID: 38375538; PMCID: PMC11021615.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    6. Safety and tolerability of intravenous immunoglobulin infusion in Down syndrome regression disorder. Am J Med Genet A. 2024 May; 194(5):e63524. Santoro JD, Jafarpour S, Khoshnood MM, Boyd NK, Vogel BN, Nguyen L, Saucier LE, Partridge R, Tiongson E, Ramos-Platt L, Nagesh D, Ho E, Rosser T, Ahsan N, Mitchell WG, Rafii MS. PMID: 38169137.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    7. Down Syndrome in a New Era for Alzheimer Disease. JAMA. 2023 12 12; 330(22):2157-2158. Rafii MS, Fortea J. PMID: 37991807.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    8. Plasma Aβ42/Aβ40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's disease. Alzheimers Dement. 2024 Feb; 20(2):1214-1224. Rissman RA, Langford O, Raman R, Donohue MC, Abdel-Latif S, Meyer MR, Wente-Roth T, Kirmess KM, Ngolab J, Winston CN, Jimenez-Maggiora G, Rafii MS, Sachdev P, West T, Yarasheski KE, Braunstein JB, Irizarry M, Johnson KA, Aisen PS, Sperling RA, AHEAD 3-45 Study team. PMID: 37932961; PMCID: PMC10916957.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    9. Hypovitaminosis D in persons with Down syndrome and autism spectrum disorder. J Neurodev Disord. 2023 10 25; 15(1):35. Boyd NK, Nguyen J, Khoshnood MM, Jiang T, Nguyen L, Mendez L, Spinazzi NA, Manning MA, Rafii MS, Santoro JD. PMID: 37880588; PMCID: PMC10599027.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    10. Alternative Diagnoses in the Work Up of Down Syndrome Regression Disorder. J Autism Dev Disord. 2023 Aug 16. Santoro JD, Khoshnood MM, Nguyen L, Vogel BN, Boyd NK, Paulsen KC, Rafii MS. PMID: 37584771.
      View in: PubMed   Mentions:    Fields:    
    11. Immunotherapy responsiveness and risk of relapse in Down syndrome regression disorder. Transl Psychiatry. 2023 08 08; 13(1):276. Santoro JD, Spinazzi NA, Filipink RA, Hayati-Rezvan P, Kammeyer R, Patel L, Sannar EA, Dwyer L, Banerjee AK, Khoshnood M, Jafarpour S, Boyd NK, Partridge R, Gombolay GY, Christy AL, Real de Asua D, Del Carmen Ortega M, Manning MA, Van Mater H, Worley G, Franklin C, Stanley MA, Brown R, Capone GT, Quinn EA, Rafii MS. PMID: 37553347; PMCID: PMC10409776.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    12. Amyloid-Lowering Monoclonal Antibodies for the Treatment of Early Alzheimer's Disease. CNS Drugs. 2023 08; 37(8):671-677. Leisher S, Bohorquez A, Gay M, Garcia V, Jones R, Baldaranov D, Rafii MS. PMID: 37470978; PMCID: PMC10439019.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    13. Trial of Solanezumab in Preclinical Alzheimer's Disease. N Engl J Med. 2023 Sep 21; 389(12):1096-1107. Sperling RA, Donohue MC, Raman R, Rafii MS, Johnson K, Masters CL, van Dyck CH, Iwatsubo T, Marshall GA, Yaari R, Mancini M, Holdridge KC, Case M, Sims JR, Aisen PS, A4 Study Team. PMID: 37458272; PMCID: PMC10559996.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    14. Detection and treatment of Alzheimer's disease in its preclinical stage. Nat Aging. 2023 05; 3(5):520-531. Rafii MS, Aisen PS. PMID: 37202518.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    15. Safety and tolerability of lumbar puncture for the evaluation of Alzheimer's disease. Alzheimers Dement (Amst). 2023 Apr-Jun; 15(2):e12431. Baldaranov D, Garcia V, Miller G, Donohue MC, Shaw LM, Weiner M, Petersen RC, Aisen P, Raman R, Rafii MS. PMID: 37091309; PMCID: PMC10113881.
      View in: PubMed   Mentions: 1  
    16. Adverse childhood experiences and the development of Down syndrome regression disorder. Am J Med Genet A. 2023 07; 191(7):1769-1782. Wang S, Patel L, Sannar EA, Khoshnood M, Boyd NK, Mendez L, Spinazzi NA, Quinn EA, Rafii MS, Santoro JD. PMID: 37017126.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    17. Immunotherapy Responsiveness and Risk of Relapse in Down Syndrome Regression Disorder. Res Sq. 2023 Feb 13. Santoro J, Spinazzi N, Filipink R, Hayati-Rezvan P, Kammeyer R, Patel L, Sannar E, Dwyer L, Banerjee A, Khoshnood M, Jafarpour S, Boyd N, Partridge R, Gombolay G, Christy A, Real de Asua D, Del Carmen Ortega M, Manning M, Van Mater H, Worley G, Franklin C, Stanley M, Brown R, Capone G, Quinn E, Rafii M. PMID: 36824719; PMCID: PMC9949176.
      View in: PubMed   Mentions:
    18. Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study. Lancet Neurol. 2023 01; 22(1):55-65. Boerwinkle AH, Gordon BA, Wisch J, Flores S, Henson RL, Butt OH, McKay N, Chen CD, Benzinger TLS, Fagan AM, Handen BL, Christian BT, Head E, Mapstone M, Rafii MS, O'Bryant S, Lai F, Rosas HD, Lee JH, Silverman W, Brickman AM, Chhatwal JP, Cruchaga C, Perrin RJ, Xiong C, Hassenstab J, McDade E, Bateman RJ, Ances BM, Alzheimer's Biomarker Consortium-Down Syndrome, Dominantly Inherited Alzheimer Network. PMID: 36517172; PMCID: PMC9979840.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    19. Editorial: Appropriate Use Recommendations for Lecanemab. J Prev Alzheimers Dis. 2023; 10(3):356. Rafii MS. PMID: 37357273.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    20. The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer's disease. Alzheimers Dement. 2023 04; 19(4):1227-1233. Rafii MS, Sperling RA, Donohue MC, Zhou J, Roberts C, Irizarry MC, Dhadda S, Sethuraman G, Kramer LD, Swanson CJ, Li D, Krause S, Rissman RA, Walter S, Raman R, Johnson KA, Aisen PS. PMID: 35971310; PMCID: PMC9929028.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    21. Assessment and Diagnosis of Down Syndrome Regression Disorder: International Expert Consensus. Front Neurol. 2022; 13:940175. Santoro JD, Patel L, Kammeyer R, Filipink RA, Gombolay GY, Cardinale KM, Real de Asua D, Zaman S, Santoro SL, Marzouk SM, Khoshnood M, Vogel BN, Tanna R, Pagarkar D, Dhanani S, Ortega MDC, Partridge R, Stanley MA, Sanders JS, Christy A, Sannar EM, Brown R, McCormick AA, Van Mater H, Franklin C, Worley G, Quinn EA, Capone GT, Chicoine B, Skotko BG, Rafii MS. PMID: 35911905; PMCID: PMC9335003.
      View in: PubMed   Mentions: 10  
    22. Evidence of neuroinflammation and immunotherapy responsiveness in individuals with down syndrome regression disorder. J Neurodev Disord. 2022 06 03; 14(1):35. Santoro JD, Partridge R, Tanna R, Pagarkar D, Khoshnood M, Rehmani M, Kammeyer RM, Gombolay GY, Fisher K, Conravey A, El-Dahr J, Christy AL, Patel L, Manning MA, Van Mater H, Rafii MS, Quinn EA. PMID: 35659536; PMCID: PMC9164321.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    23. Safety, Tolerability, and Immunogenicity of the ACI-24 Vaccine in Adults With Down Syndrome: A Phase 1b Randomized Clinical Trial. JAMA Neurol. 2022 06 01; 79(6):565-574. Rafii MS, Sol O, Mobley WC, Delpretti S, Skotko BG, Burke AD, Sabbagh MN, Yuan SH, Rissman RA, Pulsifer M, Evans C, Evans AC, Beth G, Fournier N, Gray JA, Dos Santos AM, Hliva V, Vukicevic M, Kosco-Vilbois M, Streffer J, Pfeifer A, Feldman HH. PMID: 35532913; PMCID: PMC9086937.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    24. Early-stage Alzheimer disease: getting trial-ready. Nat Rev Neurol. 2022 07; 18(7):389-399. Aisen PS, Jimenez-Maggiora GA, Rafii MS, Walter S, Raman R. PMID: 35379951; PMCID: PMC8978175.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    25. Conducting clinical trials in persons with Down syndrome: summary from the NIH INCLUDE Down syndrome clinical trials readiness working group. J Neurodev Disord. 2022 03 23; 14(1):22. Baumer NT, Becker ML, Capone GT, Egan K, Fortea J, Handen BL, Head E, Hendrix JE, Litovsky RY, Strydom A, Tapia IE, Rafii MS. PMID: 35321660; PMCID: PMC8942061.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    26. Development of treatments for Down syndrome. Lancet Neurol. 2022 01; 21(1):22-23. Rafii MS. PMID: 34942129.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    27. Alzheimer's disease associated with Down syndrome: a genetic form of dementia. Lancet Neurol. 2021 11; 20(11):930-942. Fortea J, Zaman SH, Hartley S, Rafii MS, Head E, Carmona-Iragui M. PMID: 34687637; PMCID: PMC9387748.
      View in: PubMed   Mentions: 59     Fields:    Translation:Humans
    28. Increased Autoimmunity in Individuals With Down Syndrome and Moyamoya Disease. Front Neurol. 2021; 12:724969. Santoro JD, Lee S, Wang AC, Ho E, Nagesh D, Khoshnood M, Tanna R, Durazo-Arvizu RA, Manning MA, Skotko BG, Steinberg GK, Rafii MS. PMID: 34566869; PMCID: PMC8455812.
      View in: PubMed   Mentions: 10  
    29. Feasibility study for detection of retinal amyloid in clinical trials: The Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial. Alzheimers Dement (Amst). 2021; 13(1):e12199. Ngolab J, Donohue M, Belsha A, Salazar J, Cohen P, Jaiswal S, Tan V, Gessert D, Korouri S, Aggarwal NT, Alber J, Johnson K, Jicha G, van Dyck C, Lah J, Salloway S, Sperling RA, Aisen PS, Rafii MS, Rissman RA. PMID: 34430703; PMCID: PMC8369843.
      View in: PubMed   Mentions: 12  
    30. Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease: A Truncated Randomized Phase 2b/3 Clinical Trial. JAMA Neurol. 2021 03 01; 78(3):293-301. Sperling R, Henley D, Aisen PS, Raman R, Donohue MC, Ernstrom K, Rafii MS, Streffer J, Shi Y, Karcher K, Raghavan N, Tymofyeyev Y, Bogert J, Brashear HR, Novak G, Thipphawong J, Saad ZS, Kolb H, Rofael H, Sanga P, Romano G. PMID: 33464300; PMCID: PMC7816119.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCTClinical Trials
    31. Integrating Biomarker Outcomes into Clinical Trials for Alzheimer's Disease in Down Syndrome. J Prev Alzheimers Dis. 2021; 8(1):48-51. Rafii MS, Zaman S, Handen BL. PMID: 33336224; PMCID: PMC8279390.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    32. Plasma Total-Tau and Neurofilament Light Chain as Diagnostic Biomarkers of Alzheimer's Disease Dementia and Mild Cognitive Impairment in Adults with Down Syndrome. J Alzheimers Dis. 2021; 79(2):671-681. Petersen ME, Rafii MS, Zhang F, Hall J, Julovich D, Ances BM, Schupf N, Krinsky-McHale SJ, Mapstone M, Silverman W, Lott I, Klunk W, Head E, Christian B, Foroud T, Lai F, Diana Rosas H, Zaman S, Wang MC, Tycko B, Lee JH, Handen B, Hartley S, Fortea J, O'Bryant S, Alzheimer’s Biomarker Consortium –Down Syndrome (ABC-DS). PMID: 33337378; PMCID: PMC8273927.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    33. The search for Alzheimer disease therapeutics - same targets, better trials? Nat Rev Neurol. 2020 11; 16(11):597-598. Rafii MS, Aisen PS. PMID: 32963375.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    34. The AT(N) framework for Alzheimer's disease in adults with Down syndrome. Alzheimers Dement (Amst). 2020; 12(1):e12062. Rafii MS, Ances BM, Schupf N, Krinsky-McHale SJ, Mapstone M, Silverman W, Lott I, Klunk W, Head E, Christian B, Lai F, Rosas HD, Zaman S, Petersen ME, Strydom A, Fortea J, Handen B, O'Bryant S. PMID: 33134477; PMCID: PMC7588820.
      View in: PubMed   Mentions: 19  
    35. Neurologic complications of Down syndrome: a systematic review. J Neurol. 2021 Dec; 268(12):4495-4509. Santoro JD, Pagarkar D, Chu DT, Rosso M, Paulsen KC, Levitt P, Rafii MS. PMID: 32920658.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    36. Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease Dementia: A Randomized Clinical Trial. JAMA Neurol. 2020 09 01; 77(9):1099-1109. Craft S, Raman R, Chow TW, Rafii MS, Sun CK, Rissman RA, Donohue MC, Brewer JB, Jenkins C, Harless K, Gessert D, Aisen PS. PMID: 32568367; PMCID: PMC7309571.
      View in: PubMed   Mentions: 120     Fields:    Translation:Humans
    37. Alzheimer's Disease in Down Syndrome: Progress in the Design and Conduct of Drug Prevention Trials. CNS Drugs. 2020 08; 34(8):785-794. Rafii MS. PMID: 32506291; PMCID: PMC7395870.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimals
    38. Proteomic profiles for Alzheimer's disease and mild cognitive impairment among adults with Down syndrome spanning serum and plasma: An Alzheimer's Biomarker Consortium-Down Syndrome (ABC-DS) study. Alzheimers Dement (Amst). 2020; 12(1):e12039. Petersen ME, Zhang F, Schupf N, Krinsky-McHale SJ, Hall J, Mapstone M, Cheema A, Silverman W, Lott I, Rafii MS, Handen B, Klunk W, Head E, Christian B, Foroud T, Lai F, Rosas HD, Zaman S, Ances BM, Wang MC, Tycko B, Lee JH, O'Bryant S, Alzheimer's Biomarker Consortium – Down Syndrome (ABC-DS). PMID: 32626817; PMCID: PMC7327223.
      View in: PubMed   Mentions: 13  
    39. Further understanding the connection between Alzheimer's disease and Down syndrome. Alzheimers Dement. 2020 07; 16(7):1065-1077. Snyder HM, Bain LJ, Brickman AM, Carrillo MC, Esbensen AJ, Espinosa JM, Fernandez F, Fortea J, Hartley SL, Head E, Hendrix J, Kishnani PS, Lai F, Lao P, Lemere C, Mobley W, Mufson EJ, Potter H, Zaman SH, Granholm AC, Rosas HD, Strydom A, Whitten MS, Rafii MS. PMID: 32544310; PMCID: PMC8865308.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    40. Initiation of symptomatic medication in Alzheimer's disease clinical trials: Hypothetical versus treatment policy approach. Alzheimers Dement. 2020 05; 16(5):797-803. Donohue MC, Model F, Delmar P, Volye N, Liu-Seifert H, Rafii MS, Aisen PS, Alzheimer's Disease Neuroimaging Initiative. PMID: 32270600; PMCID: PMC8317593.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    41. Down syndrome. Nat Rev Dis Primers. 2020 02 06; 6(1):9. Antonarakis SE, Skotko BG, Rafii MS, Strydom A, Pape SE, Bianchi DW, Sherman SL, Reeves RH. PMID: 32029743; PMCID: PMC8428796.
      View in: PubMed   Mentions: 237     Fields:    Translation:Humans
    42. Diminished Blood Pressure Profiles in Children With Down Syndrome. Hypertension. 2020 03; 75(3):819-825. Santoro JD, Lee S, Mlynash M, Mayne EW, Rafii MS, Skotko BG. PMID: 31928114.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    43. Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease: A Randomized Clinical Trial. JAMA Neurol. 2019 Oct 01; 76(10):1219-1229. van Dyck CH, Nygaard HB, Chen K, Donohue MC, Raman R, Rissman RA, Brewer JB, Koeppe RA, Chow TW, Rafii MS, Gessert D, Choi J, Turner RS, Kaye JA, Gale SA, Reiman EM, Aisen PS, Strittmatter SM. PMID: 31329216; PMCID: PMC6646979.
      View in: PubMed   Mentions: 61     Fields:    
    44. Predicting the course of Alzheimer's progression. Brain Inform. 2019 Jun 28; 6(1):6. Iddi S, Li D, Aisen PS, Rafii MS, Thompson WK, Donohue MC, Alzheimer’s Disease Neuroimaging Initiative. PMID: 31254120; PMCID: PMC6598897.
      View in: PubMed   Mentions: 10  
    45. Alzheimer's Disease Clinical Trials: Moving Toward Successful Prevention. CNS Drugs. 2019 02; 33(2):99-106. Rafii MS, Aisen PS. PMID: 30560544; PMCID: PMC6367028.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    46. Prevalence and Severity of Alzheimer Disease in Individuals With Down Syndrome. JAMA Neurol. 2019 02 01; 76(2):142-143. Rafii MS, Santoro SL. PMID: 30452497.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    47. Plasma Neurofilament Light and Alzheimer's Disease Biomarkers in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI). J Alzheimers Dis. 2019; 70(1):131-138. Rafii MS, Donohue MC, Matthews DC, Muranevici G, Ness S, O'Bryant SE, Rissman RA. PMID: 31156181.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    48. Down syndrome. Handb Clin Neurol. 2019; 167:321-336. Rafii MS, Kleschevnikov AM, Sawa M, Mobley WC. PMID: 31753140.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    49. Tau PET Imaging for Staging of Alzheimer's Disease in Down Syndrome. Dev Neurobiol. 2019 07; 79(7):711-715. Rafii MS. PMID: 30536948.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimals
    50. Bayesian latent time joint mixed-effects model of progression in the Alzheimer's Disease Neuroimaging Initiative. Alzheimers Dement (Amst). 2018; 10:657-668. Li D, Iddi S, Thompson WK, Rafii MS, Aisen PS, Donohue MC. PMID: 30456292; PMCID: PMC6234901.
      View in: PubMed   Mentions: 10  
    51. Diagnostic biomarkers of Alzheimer's disease in Down syndrome. Lancet Neurol. 2018 10; 17(10):831-832. Rafii MS. PMID: 30172623.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    52. Estimating the Evolution of Disease in the Parkinson's Progression Markers Initiative. Neurodegener Dis. 2018; 18(4):173-190. Iddi S, Li D, Aisen PS, Rafii MS, Litvan I, Thompson WK, Donohue MC. PMID: 30089306; PMCID: PMC6314496.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    53. Adeno-Associated Viral Vector (Serotype 2)-Nerve Growth Factor for Patients With Alzheimer Disease: A Randomized Clinical Trial. JAMA Neurol. 2018 07 01; 75(7):834-841. Rafii MS, Tuszynski MH, Thomas RG, Barba D, Brewer JB, Rissman RA, Siffert J, Aisen PS, AAV2-NGF Study Team. PMID: 29582053; PMCID: PMC5885277.
      View in: PubMed   Mentions: 78     Fields:    Translation:HumansCells
    54. Outcome Measures for Clinical Trials in Down Syndrome. Am J Intellect Dev Disabil. 2017 05; 122(3):247-281. Esbensen AJ, Hooper SR, Fidler D, Hartley SL, Edgin J, d'Ardhuy XL, Capone G, Conners FA, Mervis CB, Abbeduto L, Rafii MS, Krinsky-McHale SJ, Urv T, Outcome Measures Working Group. PMID: 28452584; PMCID: PMC5424621.
      View in: PubMed   Mentions: 70     Fields:    Translation:Humans
    55. Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomal-dominant Alzheimer's disease. Alzheimers Dement. 2017 Nov; 13(11):1251-1260. Carmona-Iragui M, Balasa M, Benejam B, Alcolea D, Fernández S, Videla L, Sala I, Sánchez-Saudinós MB, Morenas-Rodriguez E, Ribosa-Nogué R, Illán-Gala I, Gonzalez-Ortiz S, Clarimón J, Schmitt F, Powell DK, Bosch B, Lladó A, Rafii MS, Head E, Molinuevo JL, Blesa R, Videla S, Lleó A, Sánchez-Valle R, Fortea J. PMID: 28463681; PMCID: PMC5660938.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    56. A phase 3 trial of IV immunoglobulin for Alzheimer disease. Neurology. 2017 May 02; 88(18):1768-1775. Relkin NR, Thomas RG, Rissman RA, Brewer JB, Rafii MS, van Dyck CH, Jack CR, Sano M, Knopman DS, Raman R, Szabo P, Gelmont DM, Fritsch S, Aisen PS, Alzheimer's Disease Cooperative Study. PMID: 28381506; PMCID: PMC5409846.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansCTClinical Trials
    57. PET Imaging of Tau Pathology and Relationship to Amyloid, Longitudinal MRI, and Cognitive Change in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI). J Alzheimers Dis. 2017; 60(2):439-450. Rafii MS, Lukic AS, Andrews RD, Brewer J, Rissman RA, Strother SC, Wernick MN, Pennington C, Mobley WC, Ness S, Matthews DC, Down Syndrome Biomarker Initiative and the Alzheimer’s Disease Neuroimaging Initiative. PMID: 28946567.
      View in: PubMed   Mentions: 50     Fields:    Translation:Humans
    58. A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Oral ELND005 (scyllo-Inositol) in Young Adults with Down Syndrome without Dementia. J Alzheimers Dis. 2017; 58(2):401-411. Rafii MS, Skotko BG, McDonough ME, Pulsifer M, Evans C, Doran E, Muranevici G, Kesslak P, Abushakra S, Lott IT, ELND005-DS Study Group. PMID: 28453471; PMCID: PMC5777855.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    59. Targeting tau protein in Alzheimer's disease. Lancet. 2016 12 10; 388(10062):2842-2844. Rafii MS. PMID: 27863808.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    60. Improving Memory and Cognition in Individuals with Down Syndrome. CNS Drugs. 2016 07; 30(7):567-73. Rafii MS. PMID: 27272473.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimals
    61. Dissociation of Down syndrome and Alzheimer's disease effects with imaging. Alzheimers Dement (N Y). 2016 Jun; 2(2):69-81. Matthews DC, Lukic AS, Andrews RD, Marendic B, Brewer J, Rissman RA, Mosconi L, Strother SC, Wernick MN, Mobley WC, Ness S, Schmidt ME, Rafii MS. PMID: 28642933; PMCID: PMC5477635.
      View in: PubMed   Mentions: 30  
    62. The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer's disease biomarkers in down syndrome. Front Behav Neurosci. 2015; 9:239. Rafii MS, Wishnek H, Brewer JB, Donohue MC, Ness S, Mobley WC, Aisen PS, Rissman RA. PMID: 26441570; PMCID: PMC4568340.
      View in: PubMed   Mentions: 44  
    63. Advances in Alzheimer's disease drug development. BMC Med. 2015 Mar 25; 13:62. Rafii MS, Aisen PS. PMID: 25857341; PMCID: PMC4373002.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    64. Pro: Are we ready to translate Alzheimer's disease modifying therapies to people with Down syndrome? Alzheimers Res Ther. 2014; 6(5-8):60. Rafii MS. PMID: 25478025; PMCID: PMC4255529.
      View in: PubMed   Mentions: 2     Fields:    
    65. A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease. Alzheimers Dement. 2014 Sep; 10(5):571-81. Rafii MS, Baumann TL, Bakay RA, Ostrove JM, Siffert J, Fleisher AS, Herzog CD, Barba D, Pay M, Salmon DP, Chu Y, Kordower JH, Bishop K, Keator D, Potkin S, Bartus RT. PMID: 24411134.
      View in: PubMed   Mentions: 84     Fields:    Translation:HumansCellsCTClinical Trials
    66. Preclinical Alzheimer's disease therapeutics. J Alzheimers Dis. 2014; 42 Suppl 4:S545-9. Rafii MS. PMID: 25079804.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimals
    67. Neuropsychiatric symptoms and regional neocortical atrophy in mild cognitive impairment and Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2014 Mar; 29(2):159-65. Rafii MS, Taylor CS, Kim HT, Desikan RS, Fleisher AS, Katibian D, Brewer JB, Dale AM, Aisen PS. PMID: 24164929; PMCID: PMC5351414.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    68. The National Task Group on Intellectual Disabilities and Dementia Practices consensus recommendations for the evaluation and management of dementia in adults with intellectual disabilities. Mayo Clin Proc. 2013 Aug; 88(8):831-40. Moran JA, Rafii MS, Keller SM, Singh BK, Janicki MP, American Academy of Developmental Medicine and Dentistry, Rehabilitation Research and Training Center on Aging With Developmental Disabilities, University of , American Association on Intellectual and Developmental Disabilities. PMID: 23849993.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    69. Update on Alzheimer's disease therapeutics. Rev Recent Clin Trials. 2013 Jun; 8(2):110-8. Rafii MS. PMID: 23859061.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    70. Down's syndrome and Alzheimer's disease: towards secondary prevention. Nat Rev Drug Discov. 2012 09; 11(9):655-6. Ness S, Rafii M, Aisen P, Krams M, Silverman W, Manji H. PMID: 22935789.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansPHPublic Health
    71. Comparison of the memory performance index with standard neuropsychological measures of cognition. Am J Alzheimers Dis Other Demen. 2011 05; 26(3):235-9. Rafii MS, Taylor C, Coutinho A, Kim K, Galasko D. PMID: 21406427; PMCID: PMC3568924.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansPHPublic Health
    72. Functional brain imaging in the clinical assessment of consciousness. PLoS Biol. 2010 Nov 30; 8(11):e1000548. Rafii MS, Brewer JB. PMID: 21151340; PMCID: PMC2994656.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    73. The pulse of drug development for Alzheimer's disease. Rev Recent Clin Trials. 2010 Jan; 5(1):57-62. Rafii MS. PMID: 20205688.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsPHPublic Health
    74. High-throughput, fully automated volumetry for prediction of MMSE and CDR decline in mild cognitive impairment. Alzheimer Dis Assoc Disord. 2009 Apr-Jun; 23(2):139-45. Kovacevic S, Rafii MS, Brewer JB, Alzheimer's Disease Neuroimaging Initiative. PMID: 19474571; PMCID: PMC2688740.
      View in: PubMed   Mentions: 57     Fields:    Translation:Humans
    75. Recent developments in Alzheimer's disease therapeutics. BMC Med. 2009 Feb 19; 7:7. Rafii MS, Aisen PS. PMID: 19228370; PMCID: PMC2649159.
      View in: PubMed   Mentions: 71     Fields:    Translation:Humans
    76. Primary care screening for dementia and mild cognitive impairment. JAMA. 2008 Mar 12; 299(10):1132; author reply 1133-4. Rafii MS, Galasko D. PMID: 18334686.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansPHPublic Health
    77. Biglycan binds to alpha- and gamma-sarcoglycan and regulates their expression during development. J Cell Physiol. 2006 Nov; 209(2):439-47. Rafii MS, Hagiwara H, Mercado ML, Seo NS, Xu T, Dugan T, Owens RT, Hook M, McQuillan DJ, Young MF, Fallon JR. PMID: 16883602; PMCID: PMC2929672.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansAnimalsCells
    78. Case 14: a woman with bilateral Bell's palsy. MedGenMed. 2006 Oct 31; 8(4):23. Rafii MS. PMID: 17415306; PMCID: PMC1868343.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    79. Compendium of cerebrovascular diseases. Int Rev Psychiatry. 2006 Oct; 18(5):395-407. Rafii MS, Hillis AE. PMID: 17085359.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    80. Biglycan regulates the expression and sarcolemmal localization of dystrobrevin, syntrophin, and nNOS. FASEB J. 2006 Aug; 20(10):1724-6. Mercado ML, Amenta AR, Hagiwara H, Rafii MS, Lechner BE, Owens RT, McQuillan DJ, Froehner SC, Fallon JR. PMID: 16807372; PMCID: PMC3056440.
      View in: PubMed   Mentions: 32     Fields:    Translation:AnimalsCells
    81. Orolingual angioedema associated with ACE inhibitor use after rtPA treatment of acute stroke. Neurology. 2005 Dec 27; 65(12):1906. Rafii MS, Koenig M, Ziai WC. PMID: 16380611.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    Michael's Networks
    Concepts (212)
    Derived automatically from this person's publications.
    Co-Authors (35)
    People in Profiles who have published with this person.
    Similar People (59)
    People who share similar concepts with this person.
    Same Department
    Search Department